Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial - The Lancet Respiratory Medicine
Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review | Arthritis Research & Therapy | Full Text
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial -
Olumiant Price Information | With or Without Insurance | Olumiant® ( baricitinib) tablets
Oral surveillance and JAK inhibitor safety: the theory of relativity | Nature Reviews Rheumatology
Dosing & Administration | Alopecia Areata | Olumiant® (baricitinib)
Drug vignettes: Baricitinib - The Centre for Evidence-Based Medicine
Frontiers | Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 | NEJM
Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID‐19 - Jorgensen - 2020 - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Wiley Online Library
Olumiant Approved for Severe Alopecia Areata - MPR
Healthcare | Free Full-Text | Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
Novel Therapies in Rheumatoid Arthritis: From Clinical Trials to Practice Points (Transcript)
Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro | Journal of Neuroinflammation | Full Text
Olumiant Dosage/Direction for Use | MIMS Thailand
BREEZE-AD-PEDS: First Data for Baricitinib in Childhood Eczema
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose | Fierce Pharma
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment | The Journal of Rheumatology
Two Phase 3 Trials of Baricitinib for Alopecia Areata | NEJM
Baricitinib for Hospitalized Patients with COVID-19 - Ontario COVID-19 Science Advisory Table
PulmCrit - Baricitinib for COVID-19: The rise of the jakinibs
Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice - ACR Meeting Abstracts
Medicina | Free Full-Text | Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study
